

**Columbia Threadneedle (Lux) I**  
Société d'Investissement à Capital Variable  
Registered Office: 31, Z.A. Bourmicht, L-8070 Bertrange  
Grand Duchy of Luxembourg  
R.C.S. Luxembourg B 50 216  
(the “SICAV”)

## **NOTICE TO THE SHAREHOLDERS OF**

### **CT (Lux) GLOBAL FOCUS**

#### **(THE “PORTFOLIO”)**

#### **IMPORTANT**

**This document is important and requires your immediate attention. If you are in any doubt about the content of this document, you should seek independent professional advice.**

**If you have sold or transferred your Shares in Columbia Threadneedle (Lux) I, please pass this document at once to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee as soon as possible.**

**The board of directors of the SICAV accept responsibility for the accuracy of the information contained in this notice.**

11 July 2025

Dear Shareholder,

**Important information: Amendment to the investment policy to remove the restriction on investment in companies involved in conventional weapons - no action required.**

As you are an investor in the Portfolio, we are writing to inform you that the Board of Directors of the SICAV (the “**Board**”) are amending the exclusion policy to increase the Portfolio’s ability to invest in companies that are involved in the conventional weapons sector.

The Portfolio will continue to be categorised as promoting environmental or social characteristics under Article 8 of the EU Regulation 2019/2088 on sustainability-related disclosures in the financial services sector (known as the Sustainable Finance Disclosure Regulation or “**SFDR**”).

The amended exclusion policy will be adopted from 13 August 2025 (the “**Effective Date**”).

For any capitalised terms that are not specifically defined within this letter, please refer to the definition in the Hong Kong offering documents.

#### **What is changing?**

The Portfolio will continue to promote environmental and social characteristics by integrating a range of responsible investment measures into the investment decision-making process, as well as ensuring that the companies in which the Portfolio invests follow good governance practices.

However, the Portfolio is currently excluded from investing in companies that derive more than 10% of their revenue through involvement in conventional weapons, which includes military weapons and civilian firearms. From the Effective Date, these exclusions will no longer apply.

All other features of the Portfolio will remain unchanged, including the exclusions on companies involved in controversial weapons. Following these changes, the following exclusions will remain in place, and will be disclosed in the Portfolio's SFDR Article 10 disclosure, available at [www.columbiathreadneedle.com](http://www.columbiathreadneedle.com)<sup>1</sup>.

Threshold Exclusions		
Exclusion	Factor	Revenue Threshold
Tobacco	Production	5%
Thermal Coal	Power Generation Extraction	30% 30%
Nuclear Weapons	Indirect involvement: weapons systems, support services, exclusive delivery platforms, exclusive delivery platform components	5%
Full Exclusions		
Controversial Weapons		
Nuclear Weapons - Direct involvement: issuers involved in warheads and missiles, fissile material, exclusive-use components		

### Why are we making these changes?

The Investment Manager of the Portfolio believes that there is a strong case for investment in companies involved in the defence industry. Increased governmental spending on defence means it is likely that the number of companies with defence exposure (particularly in the technology and telecommunication sectors) will rise. This is expected to increase the investment opportunities available for the Portfolio and in turn could enhance performance returns.

The Portfolio will continue to be prohibited from investing in companies involved in controversial weapons, including anti-personnel mines, cluster bombs, chemical and biological weapons. These weapons are banned under international conventions and protocols. Further information on our controversial weapons policy is available in the Prospectus and on our website [www.columbiathreadneedle.com](http://www.columbiathreadneedle.com)<sup>1</sup>.

Shareholders should note that we do not expect these amendments to the investment policy to result in significant changes to the way in which the Portfolio is currently managed or its risk profile.

### What do I need to do?

You do not need to do anything as a result of these changes, which will take effect automatically on the Effective Date.

### What can I do if I disagree with the changes?

Shareholders may redeem their Shares in the Portfolio, or exchange their Shares into Shares of an alternative Portfolio of the SICAV which is authorised by the SFC in Hong Kong, free of any charges, by submitting a written request to the Authorised Sub-Distributor until 15.00 Luxembourg time on 12 August 2025. Such redemption or exchange requests will be processed in the normal manner in accordance with the Hong Kong offering documents. The SFC's authorisation is not a recommendation or endorsement of the SICAV or its Portfolios nor does it guarantee the commercial merits of the SICAV or its Portfolios or their performance. It does not mean the SICAV or its Portfolios are suitable for all investors nor is it an endorsement of the suitability of the SICAV or its Portfolios for any particular investor or class of investors. Please refer to the Hong Kong offering documents of the SICAV and its Portfolios for further details. If Shareholders take no action, they will retain their Shares in the Portfolio after the changes become effective.

<sup>1</sup> Please note that this website has not been reviewed by the SFC. The website is not specifically directed to Hong Kong residents and may contain information with respect to non-SFC authorised funds of the SICAV which are not available for public offer in Hong Kong.

### **Additional information**

The current Hong Kong offering documents, the articles of association of the SICAV and the most recent annual and semi-annual reports are available free of charge at the office of the Hong Kong Representative during normal business hours and on the website [www.columbiathreadneedle.com](http://www.columbiathreadneedle.com)<sup>1</sup>. The updated version of the SFDR RTS Annex which will reflect the changes detailed above will be available (in English language only) free of charge on the website [www.columbiathreadneedle.com](http://www.columbiathreadneedle.com)<sup>1</sup> in due course.

If you have any other questions regarding this notice, please contact the Hong Kong Representative, HSBC Institutional Trust Services (Asia) Limited, at 1 Queen's Road Central, Hong Kong, Attention: Transfer Agency, email: [ifshkbfxishkrep@hsbc.com.hk](mailto:ifshkbfxishkrep@hsbc.com.hk), tel: (852) 3663 5500, fax: (852) 3409 2697. Alternatively, for further assistance, please speak to your financial adviser. Please note that we are unable to provide financial or tax advice.

Yours faithfully,

The Board

天利（盧森堡）  
Société d'Investissement à Capital Variable  
註冊辦事處：31, Z.A. Bourmicht, L-8070 Bertrange  
Grand Duchy of Luxembourg  
R.C.S. Luxembourg B 50 216  
(「SICAV」)

## 天利（盧森堡）- 全球焦點基金

(「組合基金」)

### 致股東通知書

#### 重要事項

此乃重要文件，務須閣下即時垂注。如閣下對本文件的内容有任何疑問，應尋求獨立專業意見。

如閣下已出售或轉讓閣下於天利（盧森堡）的股份，請立即將本文件交予買方或承讓人，或經手出售或轉讓的股票經紀、銀行或其他代理人，以便盡快轉交買方或承讓人。

**SICAV 董事會**願就本通知書所載資料的準確性承擔責任。

親愛的股東：

**重要資訊：修訂投資政策以取消對參與常規武器的公司的投資限制 - 無需採取任何行動。**

由於閣下為組合基金的投資者，我們現致函通知閣下 **SICAV** 的董事會（「**董事會**」）現正修訂排除政策以提高組合基金投資於參與常規武器界別的公司之能力。

根據有關金融服務業內可持續性相關披露的歐盟規例2019/2088（稱為可持續金融披露規例或「**SFDR**」）第8條，組合基金將繼續被分類為推動環境或社會特徵。

經修訂的排除政策將由 2025 年 8 月 13 日（「**生效日期**」）起採納。

任何詞彙如於本函件未有特別界定，請參閱香港銷售文件內的定義。

#### 更改的內容是甚麼？

組合基金將繼續透過將一系列負責任投資措施整合至其投資決策過程，以及確保組合基金所投資的公司遵循良好管治實踐來推動環境及社會特徵。

然而，組合基金目前排除投資於透過參與常規武器（包括軍用武器和民用槍械）獲得超過 10%收益的公司。由生效日期起，此等排除將不再適用。

組合基金的所有其他特點將維持不變，包括對參與爭議性武器的公司的排除。在此等更改後，以下排除仍然有效，並將在組合基金的 **SFDR** 第 10 條披露中披露，有關披露可在 [www.columbiathreadneedle.com](http://www.columbiathreadneedle.com)<sup>1</sup>查閱。

---

<sup>1</sup> 請注意，此網站並未經證監會審閱。該網站並非特別為香港居民而設，其可能載有 **SICAV** 並未經證監會認可且不可在香港作公開發售的基金之資料。

限額排除		
排除	因素	收益限額
煙草	生產	5%
動力煤	發電 開採	30% 30%
核武器	間接參與；武器系統、支援服務、專用交付平台、專用交付平台組件	5%
全面排除		
爭議性武器		
核武器 - 直接參與：參與彈頭和導彈、裂變材料、專用組件的發行人		

### 我們為甚麼要作出此等更改？

投資組合的投資經理認為，投資於參與國防工業的公司的理由充分。政府國防開支有所增加意味著擁有國防業務（尤其是在科技和電信界別）的公司數量可能會增加。預期投資組合可得的投資機會將有所增加，並進而可提升表現回報。

投資組合將繼續被禁止投資於參與爭議性武器（包括殺傷性地雷、集束炸彈、化學和生物武器）的公司。此等武器是國際公約和議定書所禁止。有關我們的爭議性武器政策的進一步資料，可在說明書及我們的網站 [www.columbiathreadneedle.com](http://www.columbiathreadneedle.com)<sup>1</sup> 查閱。

股東應注意，我們預期此等對投資政策作出的修訂不會導致組合基金目前的管理方式或其風險概況產生重大變化。

### 本人需要採取甚麼行動？

閣下無需因此等更改而採取任何行動，有關更改將於生效日期自動生效。

### 倘本人不同意有關更改，本人可以怎麼辦？

股東可藉於 2025 年 8 月 12 日下午 3 時正（盧森堡時間）前向認可代理分銷商提交書面要求，以免費贖回其在組合基金的股份或將其股份轉換為 SICAV 獲香港證監會認可的另一組合基金的股份。該等贖回或轉換要求將根據香港銷售文件按照一般方式處理。證監會之認可並非對 SICAV 或其組合基金的推薦或認許，亦不是對 SICAV 或其組合基金的商業利弊或其表現作出保證。證監會之認可並不意味 SICAV 或其組合基金適合所有投資者，亦不是認許 SICAV 或其組合基金適合任何特定投資者或投資者類別。有關進一步詳情，請參閱 SICAV 及其組合基金的香港銷售文件。若股東不採取任何行動，其將於有關更改生效後把其股份保留在組合基金內。

### 其他資料

現有的香港銷售文件、SICAV 的組織章程細則及最新的年度及半年度報告將於正常辦公時間內在香港代表的辦事處及網站 [www.columbiathreadneedle.com](http://www.columbiathreadneedle.com)<sup>1</sup> 可供免費索取。SFDR RTS 附錄的已更新版本將反映上文詳載的更改，將於適當時候在網站 [www.columbiathreadneedle.com](http://www.columbiathreadneedle.com)<sup>1</sup> 可供免費索取（僅備有英文版）。

閣下如就本通知書有任何其他疑問，請聯絡香港代表 – 滙豐機構信託服務（亞洲）有限公司，地址為香港皇后大道中 1 號（收件人：過戶代理），電郵：[ifshkbfaxishkrep@hsbc.com.hk](mailto:ifshkbfaxishkrep@hsbc.com.hk)；電話：(852) 3663 5500；傳真：(852) 3409 2697。或者，如需進一步協助，請諮詢閣下的財務顧問。請注意，我們無法提供財務或稅務意見。

董事會

謹啟

2025 年 7 月 11 日